HC Wainwright Issues Pessimistic Estimate for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at HC Wainwright lowered their Q2 2026 earnings estimates for Madrigal Pharmaceuticals in a research report issued on Thursday, May 7th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of ($3.01) for the quarter, down from their previous forecast of ($0.89). HC Wainwright has a “Buy” rating and a $620.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($5.59) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at $0.18 EPS, FY2026 earnings at ($7.07) EPS, FY2027 earnings at $11.78 EPS and FY2028 earnings at $35.23 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) earnings per share for the quarter, topping the consensus estimate of ($3.61) by $0.36. The company had revenue of $311.34 million during the quarter, compared to analyst estimates of $301.05 million. Madrigal Pharmaceuticals had a negative net margin of 27.32% and a negative return on equity of 50.15%. Madrigal Pharmaceuticals’s revenue was up 126.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.32) earnings per share.

Several other research analysts have also weighed in on MDGL. The Goldman Sachs Group reaffirmed a “buy” rating and set a $571.00 target price on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. Canaccord Genuity Group reduced their price target on shares of Madrigal Pharmaceuticals from $587.00 to $578.00 and set a “buy” rating on the stock in a research report on Thursday. Evercore set a $649.00 price target on shares of Madrigal Pharmaceuticals in a research report on Thursday. Citizens Jmp increased their price target on shares of Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 20th. Finally, Barclays started coverage on shares of Madrigal Pharmaceuticals in a research report on Tuesday, January 27th. They set an “overweight” rating and a $964.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $682.07.

Madrigal Pharmaceuticals Trading Down 2.6%

Shares of MDGL stock opened at $497.03 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.50 and a quick ratio of 3.16. The firm has a market cap of $11.46 billion, a PE ratio of -38.83 and a beta of -1.04. The company has a 50-day moving average of $490.94 and a two-hundred day moving average of $508.12. Madrigal Pharmaceuticals has a 1-year low of $265.00 and a 1-year high of $615.00.

Insider Transactions at Madrigal Pharmaceuticals

In related news, CEO William John Sibold sold 1,663 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $431.94, for a total value of $718,316.22. Following the sale, the chief executive officer owned 161,829 shares of the company’s stock, valued at $69,900,418.26. This trade represents a 1.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Shannon T. Kelley sold 360 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $431.94, for a total transaction of $155,498.40. Following the completion of the sale, the general counsel directly owned 12,138 shares in the company, valued at approximately $5,242,887.72. This trade represents a 2.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,098 shares of company stock valued at $2,626,254 over the last quarter. Insiders own 17.60% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC acquired a new stake in Madrigal Pharmaceuticals during the fourth quarter worth approximately $29,000. First Horizon Corp acquired a new stake in Madrigal Pharmaceuticals during the third quarter worth approximately $34,000. Global Retirement Partners LLC raised its holdings in Madrigal Pharmaceuticals by 221.7% during the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 51 shares in the last quarter. Aventura Private Wealth LLC acquired a new stake in Madrigal Pharmaceuticals during the fourth quarter worth approximately $36,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Madrigal Pharmaceuticals during the third quarter worth approximately $39,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Madrigal Pharmaceuticals and reiterated a $620 price target, while also lifting its FY2028 EPS estimate, signaling confidence in the company’s longer-term earnings potential.
• Neutral Sentiment: A separate article highlighted valuation after Madrigal’s strong Q1 2026 earnings and Rezdiffra sales growth, which may support the stock but did not include a new formal rating change.
• Neutral Sentiment: Reported short interest data showed zero shares outstanding in the latest update, so it does not appear to be a meaningful current trading factor.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to $(7.07) from $(3.11), reflecting a deeper expected loss for the year and potentially weighing on investor sentiment.
• Negative Sentiment: The firm also reduced its Q2 2026 EPS estimate to $(3.01), Q3 2026 EPS to $(1.05), and Q4 2026 EPS to $0.18, implying weaker near-term earnings momentum for Madrigal Pharmaceuticals.
• Negative Sentiment: HC Wainwright lowered its FY2027 EPS forecast to $11.78 from $13.25, suggesting some moderation in the company’s medium-term earnings outlook.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-? agonist in Phase 3 development for the treatment of NASH.